| |
Thrombotech is dedicated to bringing about fundamental improvement in how stroke is treated, in order to save millions of patients from death and disability each year. Thrombotech researchers are committed to identifying the basic problems impeding treatment within the current methods and medications used, and will continue to create innovative solutions that will soon make the current inability to effectively treat 85% of embolic stroke patients a thing of the past.
Thrombotech believes it can realize this vision through the scientific advancement of its innovation, the peptide THR-18, whose performance in lab examinations to date has shown strong potential.
THR-18’s unique mechanism of action has been proven by experimental evidence to not only be effective in cases of acute ischemic stroke, but also against heart attacks, traumatic brain injury, pulmonary embolisms and occluded arteries and veins in the legs and arms.
|
|
|
|
| |
|
|
